A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects
with Advanced or Metastatic Solid Tumors
NC318 is a monoclonal antibody, a first in class immunomedicine that targets Siglec-5 (S15).
S15 suppresses the immune system, specifically T cells which fight infection and cancer. NC318
blocks the immune system suppression caused by S15 and restores T cell function. NC318 not
only restores T cell function and anti-tumor immunity.
Many immunotherapies target the PD-1 (programed death) and PD-L1 (PD ligand) pathways to
fight cancer. The PD-1 / PD-L1 and S15 pathways do not overlap so NC318 may be suited to
treat patients who are not responding to PD-1/PD-L1 directed cancer therapies.
Our dedicated physicians and staff are determined to bring the latest advances in medical
research here, so you don’t have to go elsewhere for world class medicine. Gettysburg Cancer
Center is the first site in the world to treat a patient with this promising new drug.
If you are interested in more information on this study, please contact us. Refer to the NextCure
Study Protocol NC318-01. You can also find information on this study by going to
clinicaltrials.gov website and searching for NCT03665285.